Patent · US Active

TNF-alpha variant fusion molecules

US12410223B2 · kind B2 · utility

0Cited by
27References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 8, 2024
Grant dateSep 9, 2025
Priority date
Expiry dateNov 8, 2044

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to TNF-alpha variants and TNF-alpha variant fusion molecules and therapeutic uses of such thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.